{"id":59037,"date":"2024-03-13T22:03:13","date_gmt":"2024-03-13T21:03:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/"},"modified":"2024-03-13T22:03:13","modified_gmt":"2024-03-13T21:03:13","slug":"guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/","title":{"rendered":"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90%<\/i><\/li>\n<li>\n<i>Results pave the way for first potential FDA-approved blood test for colorectal cancer screening to meet requirements for Medicare coverage<\/i><\/li>\n<\/ul>\n<p>PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from the ECLIPSE study showing the effectiveness of its Shield<sup>TM<\/sup> blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/5\/Guardant_Box_Images_Final_4K_closed.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/22\/Guardant_Box_Images_Final_4K_closed.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/5\/Guardant_Box_Images_Final_4K_closed.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/21\/Guardant_Box_Images_Final_4K_closed.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/1330243\/5\/GuardantHealthLogo_TM_RGB-2C.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/1330243\/22\/GuardantHealthLogo_TM_RGB-2C.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/1330243\/5\/GuardantHealthLogo_TM_RGB-2C.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg\"><\/a><\/p>\n<p>\n\u201cOver 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant,\u201d said AmirAli Talasaz, Guardant Health co-CEO. \u201cWe believe the publication of the ECLIPSE study in The New England Journal of Medicine, one of the world\u2019s leading medical journals, is an endorsement of the quality of our clinical data and the potential value of the Shield test. We are confident that offering an accurate blood test has the potential to significantly reduce preventable colorectal cancer deaths.\u201d<\/p>\n<p>\nOne of the largest studies of its kind, ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode) is a 20,000+-patient registrational study to evaluate the performance of Shield compared to a screening colonoscopy. The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA).<\/p>\n<p>\nHighlights of the study results to be published in <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nejm.org%2F&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=1&amp;md5=e00b4d1b86a397af1181212ef3d40553\" rel=\"nofollow noopener\" shape=\"rect\">The New England Journal of Medicine<\/a>* show that Shield demonstrated:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n83% sensitivity in detecting individuals with CRC<\/li>\n<li>\n88% sensitivity in detecting pathology-confirmed Stages I-III<\/li>\n<li>\nSensitivity by stage of:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\n65% for pathology-confirmed Stage I; 55% for clinical Stage I<\/li>\n<li>\n100% for Stage II<\/li>\n<li>\n100% for Stage III<\/li>\n<li>\n100% for Stage IV<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\nThese results are on par with the performance of other guideline-recommended non-invasive screening modalities, where overall sensitivity in detecting colorectal cancer ranges from 74% to 92%.<sup>1<\/sup><\/p>\n<p>\n\u201cMore than 3 out of 4 Americans who die from colorectal cancer are not up to date with their recommended screening,<sup>2<\/sup> highlighting the need for a more convenient and less invasive screening method that can overcome barriers associated with traditional options,\u201d said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. \u201cThe ECLIPSE study results published today support the use of a blood test as a screening option that could help overcome these barriers and improve CRC screening rates.&#8221;<\/p>\n<p>\nPublication of ECLIPSE follows Guardant Health\u2019s <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.guardanthealth.com%2Fpress-releases%2Fpress-releases%2F2023%2FGuardant-Health-submits-premarket-approval-application-to-the-U.S.-Food-and-Drug-Administration-for-Shield-blood-test%2Fdefault.aspx&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=submission&amp;index=2&amp;md5=65e6466f5cd3002b7e45675ac7c370fe\" rel=\"nofollow noopener\" shape=\"rect\">submission<\/a> of its premarket approval (PMA) application to the U. S. Food and Drug Administration (FDA) for Shield, which included key data points from the study. Since the launch of the lab-developed version of the Shield test in May 2022, it has been used by more than 20,000 people and more than 90% of patients who were prescribed the test in the real-world clinical setting completed it. One recent study showed that CRC screening rates tripled among adults who had declined prior CRC screening when they were offered Shield. The test\u2019s sensitivity in detecting CRC, combined with this real-world adherence, suggests that Shield has the potential to detect more CRCs at a curable stage than traditional screening methods.<sup>3,4,5,6<\/sup><\/p>\n<p>\n\u201cColorectal cancer is highly treatable if caught in the early stages, yet more than 50 million people in the U.S. are still not completing their recommended screening with the methods available today,\u201d said Chris Evans, president of the Colon Cancer Coalition. \u201cThis publication gets us one step closer to having an additional option to offer patients \u2013 one that is both convenient and accessible\u2014and will help us close the screening gap.\u201d<\/p>\n<p>\nColorectal cancer is the second-leading cause of cancer deaths in the U.S. The American Cancer Society estimates that more than 150,000 people will be diagnosed with CRC in 2024<sup>7<\/sup> and it is expected to become the leading cause of cancer-related deaths by 2030 in adults aged 20-49.<sup>8<\/sup> More than 75% of people who die from CRC are not up to date with recommended screening,<sup>9<\/sup> often due to the perception that current methods such as colonoscopy or stool-based tests are invasive, time-consuming and inconvenient. Early detection, however, is crucial. When colon cancer is found at an early stage before it has spread, the 5-year relative survival rate is 91%. If the cancer has spread to distant parts of the body, the 5-year survival rate is 13%.<\/p>\n<p>\n\u201cThe results of the study are a promising step toward developing more convenient tools to detect colorectal cancer early while it is more easily treated,\u201d said corresponding author William M. Grady, MD, a gastroenterologist at Fred Hutchinson Cancer Center. \u201cThe test, which has an accuracy rate for colon cancer detection similar to stool tests used for early detection of cancer, could offer an alternative for patients who may otherwise decline current screening options.&#8221;<\/p>\n<p>\n*<i> Representatives of the media who are not able to access the article content can contact <\/i><a target=\"_blank\" href=\"mailto:press&#64;guardanthea&#108;&#116;&#104;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\"><i>&#112;&#x72;e&#x73;&#x73;&#64;&#x67;u&#x61;&#x72;&#100;&#x61;n&#x74;&#x68;&#101;&#x61;l&#x74;&#x68;&#46;&#x63;o&#x6d;<\/i><\/a><i>.<\/i><\/p>\n<p>\n<b>About the ECLIPSE study<\/b><\/p>\n<p>\nECLIPSE is a prospective registrational study to evaluate the performance of Guardant Health\u2019s blood test in detecting signs of CRC compared to a screening colonoscopy in average-risk adults between the ages of 45 and 84 from across the U.S. The ECLIPSE study included more than 200 clinical trial sites in rural and urban communities across 34 states. Study data includes 12% Black, 13% Hispanic and 7% Asian American populations. Enrollment among Black Americans was above average for a clinical trial, which is important given the disproportionate impact of CRC on the Black community.<sup>10<\/sup><\/p>\n<p>\n<b>About Shield<\/b><\/p>\n<p>\nThe Shield test for colorectal cancer screening is commercially available for eligible individuals by prescription only through healthcare professionals. This LDT (Laboratory Developed Test) is intended to be complementary to, and not a replacement for, current recommended CRC screening methods. A negative result does not rule out the presence of cancer. Patients with an abnormal blood-based screening result should be referred for a diagnostic colonoscopic evaluation.<\/p>\n<p>\nMore information about the Shield test is available at bloodbasedscreening.com.<\/p>\n<p>\n<b>About Guardant Health<\/b><\/p>\n<p>\nGuardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=59f8fecffa9a0ff331df4e261bbf9fa2\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=X+%28Twitter%29&amp;index=4&amp;md5=aec32d1a364aa0b81405630c7ce91f22\" rel=\"nofollow noopener\" shape=\"rect\">X (Twitter)<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FGuardantHealthInc&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=640751609a1d1709851d782fa11227a8\" rel=\"nofollow noopener\" shape=\"rect\">Facebook<\/a>.<\/p>\n<p>\n<b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p>\n<b>Disclosures<\/b><\/p>\n<p>\n<i>Dr. Chung and Dr. Grady are paid members of Guardant Health\u2019s ECLIPSE Steering Committee. Both advised on the design and procedure of the clinical study and data analysis.<\/i><\/p>\n<p>\n<b>References<\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nChung, D., et al. Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population. Abstract #3910067. Digestive Disease Week 2023; May 6-9, 2023; Chicago, IL.<\/li>\n<li>\nGastroenterology. 2019 Jan; 156(1): 63\u201374.e6. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Feutils%2Felink.fcgi%3Fdbfrom%3Dpubmed%26retmode%3Dref%26cmd%3Dprlinks%26id%3D30268788&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=www.ncbi.nlm.nih.gov%2Fentrez%2Feutils%2Felink.fcgi%3Fdbfrom%3Dpubmed%26amp%3Bretmode%3Dref%26amp%3Bcmd%3Dprlinks%26amp%3Bid%3D30268788&amp;index=6&amp;md5=70969b8d9772809333fffe45f2c4176c\" rel=\"nofollow noopener\" shape=\"rect\">www.ncbi.nlm.nih.gov\/entrez\/eutils\/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=30268788<\/a>. Accessed March 6, 2024.<\/li>\n<li>\nBretthauer M, L\u00f8berg M, Wieszczy P, et al.; NordICC Study Group. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022;387:1547-1556.<\/li>\n<li>\nKnudsen AB, Rutter CM, Peterse EFP, et al. Colorectal cancer screening: An updated decision analysis for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality; 2021a. Report No.: 202s.<\/li>\n<li>\nImperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Eng J Med. 2014.<\/li>\n<li>\nCoronado GD, Jenkins CL, Shuster E, et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. Epub ahead of print:23 January 2024. doi:10.1136\/gutjnl-2023-330980.<\/li>\n<li>\nAmerican Cancer Society: Colorectal Cancer Key Statistics. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fcolon-rectal-cancer%2Fabout%2Fkey-statistics.html&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=www.cancer.org%2Fcancer%2Fcolon-rectal-cancer%2Fabout%2Fkey-statistics.html&amp;index=7&amp;md5=10f8575455b7446d4266ae8a675f34e9\" rel=\"nofollow noopener\" shape=\"rect\">www.cancer.org\/cancer\/colon-rectal-cancer\/about\/key-statistics.html<\/a> Accessed online Feb 5, 2021.<\/li>\n<li>\nColorectal Cancer Alliance. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcolorectalcancer.org%2Fresources-support%2Fcommunity-support%2Fyoung-onset-support%2Fyoung-onset-crc-facts&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcolorectalcancer.org%2Fresources-support%2Fcommunity-support%2Fyoung-onset-support%2Fyoung-onset-crc-facts&amp;index=8&amp;md5=d9f51a0fc40908596cda2cee1fc074cd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/colorectalcancer.org\/resources-support\/community-support\/young-onset-support\/young-onset-crc-facts<\/a>. Accessed March 13, 2024.<\/li>\n<li>\nDoubeni CA, Fedewa SA, Levin TR, et al. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology 2019;156:63\u201374.<\/li>\n<li>\nU.S. Food &amp; Drug Administration. 2022 Drug Trials Snapshots Summary Report. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Fdrug-trials-snapshots&amp;esheet=53909650&amp;newsitemid=20240313547689&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Fdrug-trials-snapshots&amp;index=9&amp;md5=724fcc7448e26f3491ba737dee55c8aa\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots<\/a>. Accessed December 18, 2023.<\/li>\n<\/ol>\n<p>\n\u00a0<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor Contact:<\/b><br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;in&#x76;&#x65;&#115;t&#x6f;&#x72;&#115;&#64;g&#x75;&#x61;&#114;d&#x61;&#x6e;&#116;&#104;e&#x61;&#x6c;&#116;h&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#110;&#118;e&#x73;&#x74;&#111;r&#x73;&#x40;&#103;ua&#x72;&#100;&#97;n&#x74;&#x68;&#101;a&#x6c;&#x74;&#104;&#46;c&#x6f;&#x6d;<\/a><\/p>\n<p>\n<b>Media Contact:<\/b><br \/>Michael Weist<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x70;&#x72;&#101;s&#x73;&#64;g&#x75;&#x61;&#114;d&#x61;&#x6e;&#116;h&#x65;&#97;&#108;&#x74;&#x68;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#115;&#64;gua&#x72;&#x64;&#x61;&#x6e;&#116;&#104;eal&#x74;&#x68;&#x2e;&#x63;&#111;&#109;<\/a><br \/>+1 650-647-3643<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% Results pave the way for first potential FDA-approved blood test for colorectal cancer screening to meet requirements for Medicare coverage PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59037","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% Results pave the way for first potential FDA-approved blood test for colorectal cancer screening to meet requirements for Medicare coverage PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-13T21:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/22\/Guardant_Box_Images_Final_4K_closed.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine\",\"datePublished\":\"2024-03-13T21:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/\"},\"wordCount\":1641,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240313547689\\\/en\\\/2065620\\\/22\\\/Guardant_Box_Images_Final_4K_closed.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/\",\"name\":\"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240313547689\\\/en\\\/2065620\\\/22\\\/Guardant_Box_Images_Final_4K_closed.jpg\",\"datePublished\":\"2024-03-13T21:03:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240313547689\\\/en\\\/2065620\\\/22\\\/Guardant_Box_Images_Final_4K_closed.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240313547689\\\/en\\\/2065620\\\/22\\\/Guardant_Box_Images_Final_4K_closed.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine - Pharma Trend","og_description":"Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% Results pave the way for first potential FDA-approved blood test for colorectal cancer screening to meet requirements for Medicare coverage PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/","og_site_name":"Pharma Trend","article_published_time":"2024-03-13T21:03:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/22\/Guardant_Box_Images_Final_4K_closed.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine","datePublished":"2024-03-13T21:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/"},"wordCount":1641,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/22\/Guardant_Box_Images_Final_4K_closed.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/","url":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/","name":"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/22\/Guardant_Box_Images_Final_4K_closed.jpg","datePublished":"2024-03-13T21:03:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/22\/Guardant_Box_Images_Final_4K_closed.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240313547689\/en\/2065620\/22\/Guardant_Box_Images_Final_4K_closed.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59037"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59037\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}